Abstract Background: Diabetes Mellitus (DM) is a metabolic disorder characterized by the presence of chronic hyperglyc-emia accompanied by greater or lesser impairment in the metabolism of carbohydrates, lipids and proteins. DM is probably one of the oldest diseases known to man. It was first reported in Egyptian manuscript about 3000 years ago. In 1936, the distinction between type 1 and type 2 DM was clearly made. Type 2 DM was first described as a component of metabolic syndrome in 1988. The origin and etiology of DM can vary greatly but always include defects in either insulin secretion or response or in both at some point in the course of disease. Obesity is associated with an increased risk of premature death and significantly increases the risk of developing type 2 diabetes mellitus, hypertension, coronary heart disease. Dyslipidaemia is a silent pandemic affecting millions of people around the world. There is controversy of the possible benefit of liposuction or abdominoplasty in the metabolism of glucose or cholesterol. Liposuction was the second most frequently performed aesthetic operation in 2013. As with any surgery liposuction carries risks, however, in recent years, improved techniques have made liposuction safer, easier, and less painful. Thus, any intervention that immediately decreases adiposity and is relatively safe could be a viable method not only for aesthetic purpose but also for increasing the efficiency of insulin and improving metabolic profile, especially when combined with regular exercise and proper diet. Aim of Study: The aim of this study is to evaluate the effectiveness of abdominal liposuction in improving quality of life in newly diagnosed uncomplicated type 2 diabetic patients. Patients and Methods: This study will take place in plastic Surgery Department, Port Said general Hospital. As total number of cases satisfying inclusion criteria not exceed 6 cases the study period (During 2019-2020) the total sample 3x6=18 cases all will be included as comprehensive sample. Results: In our study, the mean FBG was 163±22mg/d1 preoperatively. At three months after surgery, it was 162±29mg/dl, but at six months after surgery, it was 147±  28mg/d1. The mean PPBG was 218±40mg/d1 preoperatively. At three months after surgery, it was 216±40mg/dl, but at six months after surgery, it was 200±34mg/d1. The mean HbAlc percentage was 8±0.8% preoperatively. At three months after surgery, it was 7.7±0.8%, but at six months after surgery, it was 7.6±0.8%. The mean triglyceride level 48 preoperatively. At three months after surgery, it was 162±41, but at six months after surgery, it was 159±49. The mean cholesterol was 207 ±42 preoperatively. At three months after surgery, it was 197 ±52, but at six months after surgery, it was 189±41. The HOMA-IR was 3±0.7 preoperatively. At three months after surgery, it was 2.8±0.7, but at six months after surgery, it was 2.8±0.7. All the laboratory investigations change over time among the studied patients were not statistically significant. Conclusion: So, we can conclude that large volume ab-dominal liposuction should not, by itself, be considered a clinical therapy for type 2 diabetes mellitus. Aspiration of large amounts of subcutaneous abdominal fat in diabetic patients, despite having cosmetic benefits, It does not signif-icantly improve insulin sensitivity through altering serum levels of obesity markers. Therefore, the procedure is safe and may could successfully help diabetic subjects to reduce their potential metabolic risks. Therefore, abdominal Liposuc-tion is effective scarless operation for subcutaneous adipose fatty tissue reduction.